The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease

被引:36
作者
Boucher M.-P. [3 ]
Lefebvre C. [3 ]
Chapados N.A. [1 ,2 ]
机构
[1] Institut de recherche de l'Hôpital Montfort, Hôpital Montfort, 713 Montreal Road, Ottawa, K1K 0T2, ON
[2] School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, ON
[3] La Cite, Ottawa, ON
基金
加拿大自然科学与工程研究理事会;
关键词
Environmental contaminants; Liver; Rats; Steatosis;
D O I
10.1186/s40200-015-0218-2
中图分类号
学科分类号
摘要
Background: Non alcoholic fatty liver disease (NAFLD) results from alteration in lipid synthesis and elimination mechanisms such as very-low density lipoprotein (VLDL) production and de novo lipogenesis. Persistent organic pollutants (POPs) are chemicals that were mostly used historically as pesticides, solvents, flame retardant, and other applications. Among POPs, polychlorinated biphenyls (PCB) have been recognized to be of environmental and potential toxicologic concerns. Specifically, PCB126 could act as endocrine disruptors and has recently been associated with hepatic fat accumulation. The purpose of the study was to investigate the effects of PCB126 on the molecular development of NAFLD using hepatocyte and rat models. Methods: Hepatocytes were exposed to PCB 126 for 72 h and lipid accumulation in cells was quantified by Oil-Red-O. Rats were injected with a single dose of PCB126 or vehicle. Seven days later, liver triglycerides (TAG) content was measured along with protein quantification of hepatic microsomal triglyceride transfer protein (MTP), sterol regulatory element-binding protein 1c (SREBP1c) and diacylglycerol O-acyltransferase 2 (DGAT-2). Results: Exposure to PCB126 resulted in significant increases of lipid accumulation in hepatocytes (38 %, P <0.05) and hepatic TAG concentrations (64 %, P < 0.001) in rats compared to respective control groups. Rats with fatty livers depicted lower MTP (40 %, P < 0.02), higher SREBP1c (27 %, P < 0.05) and DGAT-2 (120 %, P < 0.02) protein content levels compared to Placebo group in rats. Conclusions: It seems that exposure to PCB126 has an important emerging role in the pathophysiology of NAFLD by 1) altering elimination mechanisms such as VLDL synthesis and secretion, through MTP; and 2) increasing hepatic TAG synthesis mechanisms through DGAT 2 and SREBP1c. © 2015 Boucher et al.
引用
收藏
相关论文
共 50 条
[31]   Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention [J].
Tacke, Frank ;
Weiskirchen, Ralf .
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
[32]   Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease [J].
Heeboll, Sara ;
Thomsen, Karen Louise ;
Pedersen, Steen B. ;
Vilstrup, Hendrik ;
George, Jacob ;
Gronbaek, Henning .
WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (04) :188-198
[33]   Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease [J].
Sara Heebll ;
Karen Louise Thomsen ;
Steen B Pedersen ;
Hendrik Vilstrup ;
Jacob George ;
Henning Grnbk .
World Journal of Hepatology, 2014, 6 (04) :188-198
[34]   Interrelationships between Hepatic Fat and Insulin Resistance in Non-Alcoholic Fatty Liver Disease [J].
Lockman, Khalida A. ;
Nyirenda, Moffat J. .
CURRENT DIABETES REVIEWS, 2010, 6 (05) :341-347
[35]   Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease [J].
Duan, Xiao Yan ;
Zhao, He Ping ;
Fan, Jian Gao .
JOURNAL OF DIGESTIVE DISEASES, 2010, 11 (02) :94-100
[36]   The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J].
Liu, Qing ;
Bengmark, Stig ;
Qu, Shen .
LIPIDS IN HEALTH AND DISEASE, 2010, 9
[37]   Comparative toxicogenomic examination of the hepatic effects of PCB126 and TCDD in immature, ovariectomized C57BL/6 mice [J].
Kopec, Anna K. ;
Boverhof, Darrell R. ;
Burgoon, Lyle D. ;
Ibrahim-Aibo, Daher ;
Harkema, Jack R. ;
Tashiro, Colleen ;
Chittim, Brock ;
Zacharewski, Timothy R. .
TOXICOLOGICAL SCIENCES, 2008, 102 (01) :61-75
[38]   A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease [J].
Young, Erin Nicole ;
Doga, Murat ;
Watkins, Christine ;
Bajwa, Amandeep ;
Eason, James D. ;
Kuscu, Canan ;
Kuscu, Cem .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
[39]   Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease [J].
Yan, Hong-Mei ;
Xia, Ming-Feng ;
Wang, Yan ;
Chang, Xin-Xia ;
Yao, Xiu-Zhong ;
Rao, Sheng-Xiang ;
Zeng, Meng-Su ;
Tu, Yin-Fang ;
Feng, Ru ;
Jia, Wei-Ping ;
Liu, Jun ;
Deng, Wei ;
Jiang, Jian-Dong ;
Gao, Xin .
PLOS ONE, 2015, 10 (08)
[40]   Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease [J].
Kanbay, Mehmet ;
Bulbul, Mustafa C. ;
Copur, Sidar ;
Afsar, Baris ;
Sag, Alan A. ;
Siriopol, Dimitrie ;
Kuwabara, Masanari ;
Badarau, Silvia ;
Covic, Adrian ;
Ortiz, Alberto .
JOURNAL OF NEPHROLOGY, 2021, 34 (03) :649-659